Workflow
福瑞达再次“瘦身”:拟8840万元转让银座商管

Core Viewpoint - The company is divesting its underperforming subsidiary, Shandong Lushang Yinzhu Commercial Management Co., Ltd., to optimize its asset structure and focus on its core businesses in pharmaceuticals and cosmetics [1][4]. Summary by Sections Transaction Details - The company plans to sell its 100% stake in the subsidiary for 88.4028 million yuan, which is less than a 1% premium over its net asset value [1]. - The subsidiary has reported cumulative losses of approximately 1.5 million yuan for the first half of 2024 and 2025 [1]. - The transaction is classified as a related party transaction, as both parties are controlled by the same parent company [1]. Financial Performance - The subsidiary's profitability has declined, with net profits of 33,000 yuan in 2022 and 479,100 yuan in 2023, followed by a net loss of 623,500 yuan in 2024 and 876,800 yuan in the first half of 2025 [2]. - The revenue of the subsidiary primarily comes from managing internal real estate projects, but it faces challenges due to policy changes affecting state-owned capital in the real estate sector [2]. Strategic Implications - The divestiture is part of the company's strategy to streamline operations and focus on its main sectors, which are pharmaceuticals and cosmetics, following the exit from the real estate business in 2023 [2][3]. - The company aims to concentrate resources on its core businesses to better compete in the market [2][3]. - The company reported a 7.05% decline in revenue to 1.79 billion yuan in the first half of 2025, with a net profit decrease of 15.16% to 108 million yuan [3]. Business Segment Performance - The cosmetics segment generated 1.094 billion yuan in revenue, down 7.73%, with mixed performance among core brands [3]. - The "Yilian" brand saw a revenue increase of 23.78% to 554 million yuan, while the "Aier Doctor" brand experienced a 29.97% decline to 451 million yuan [3]. - The pharmaceutical segment also faced challenges, with a 13.87% revenue decrease to 207 million yuan in the first half of 2025 [3].